Advertisement

Selektive Serotonin-Wiederaufnahmehemmer (SSRI) bei therapieresistenten und schweren Depressionen

  • C. Baethge
  • M. Bauer
Conference paper

Zusammenfassung

  1. 1.

    Die SSRIs gehören zu den am meisten verschriebenen psychiatrischen Medikamenten. Sie werden bei leichten und mittelschweren depressi;ven Syndromen, sowie bei Angst- und Zwangsstörungen mit Erfolg ein;gesetzt.

     
  2. 2.

    Es konnte bisher nicht zweifelsfrei gezeigt werden, daß SSRIs bei thera;pieresistenten Depressionen eine effiziente Therapie darstellen. Es gibt jedoch Hinweise, daß eine Kombination von TZA und SSRIs bei thera-pieresistenten Depressionen wirksam ist.

     
  3. 3.

    Bei schweren Depressionen ist es nach der gegenwärtigen Datenlage ebenfalls fraglich, ob die SSRIs genauso wirksam sind wie trizyklische Antidepressiva (TZA)..Trizyklische Antidepressiva sollten daher bei schweren Depressionen die Medikamente der ersten Wahl bleiben.

     
  4. 4.

    Die Frage, ob SSRIs das Suizidrisiko bei depressiven Patienten erhöhen oder verringern, wird gegenwärtig kontrovers diskutiert. Sicher ist, daß SSRIs weniger Nebenwirkungen haben als TZA und in Überdosie;rungen weniger toxisch als diese sind. Dies sollte jedoch in bezug auf Therapieabbruch und Suizidrisiko nicht überschätzt werden.

     

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Altamura AC, Montgomery SA, Wernicke JF (1988) The evidence for 20 mg of fluoxetine as the optimal dose in the treatment of depression. Brit J Psychiatr 153 (suppl. 3): 109–112Google Scholar
  2. Amsterdam JD, Maislin G, Potter L (1994) Fluoxetine efficacy in treatment resistant depression. Prog Neuropsychopharmacol Biol Psychiat 18: 243–261CrossRefGoogle Scholar
  3. Anderson IM, Tomenson BM (1994) The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 8: 238–249PubMedCrossRefGoogle Scholar
  4. Anderson IM, Tomenson BM (1995) Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. Brit Med J 310: 1433–1438PubMedCrossRefGoogle Scholar
  5. Bauer M, Hellweg R, Baumgartner A (1996) Fluoxetine-induced akathisia does not reappear after switching to paroxetine. J Clin Psychiatry, im DruckGoogle Scholar
  6. Beasley CM, Sayler ME, Cunningham GE, Weiss AM, Masica DN (1990) Fluoxetine in tricyclic refractory major depressive disorder. J Affect Disorders 20: 193–200PubMedCrossRefGoogle Scholar
  7. Beasley CM, Dornseif BE, Bosomworth JC, Saylor ME, Rampsey AH, Heiligenstein JH, Thompson VL, Murphy DJ, Masica DN (1991) Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression. Br Med J 303: 685–691Google Scholar
  8. Boyer WF, Feighner JP (1991) The efficacy of selective serotonin re-uptake inhibitors in depression. In: Feighner JP, Boyer WF (eds) Selective serotonin re-uptake inhibitors. Wiley & Sons, Chichester, pp. 89–108Google Scholar
  9. Coulter DM, Pillans PI (1995) Fluoxetine and extrapyramidal side effects. Am J Psychiatry 152: 122–125PubMedGoogle Scholar
  10. Delgado PL, Price LH, Charney DS, Heninger GR (1988) Efficacy of fluvoxamine in treatment-refractory depression. J Affect Disord 15: 55–60PubMedCrossRefGoogle Scholar
  11. Dornseif BE, Dunlop SR, Potvin JH, Wernicke JF (1989) Effect of dose-escalation after low-dose fluoxetine therapy. Psychopharmacol Bull 25 (1): 71–79PubMedGoogle Scholar
  12. Edwards J (1995) Suicide and antidepressants. Brit Med J 310: 205–206PubMedCrossRefGoogle Scholar
  13. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM (1994) Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 151: 1372–1374PubMedGoogle Scholar
  14. Fuller RW, Wong DT (1987) Serotonin reuptake blockers in vitro and in vivo. J Clin Psychopharmacol 7: 14–20CrossRefGoogle Scholar
  15. Gatti F, Bellini L, Gasperini M, Perez J, Zanardi R, Smeraldi E (1996) Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry 153: 414–416PubMedGoogle Scholar
  16. Henry JA, Alexander CA, Sener EK (1995) Relative mortality from overdose of antidepressants. Brit Med J 310: 221–224PubMedCrossRefGoogle Scholar
  17. Jick SS, Den AD, Jick H (1995) Antidepressants and suicide. Brit Med J 310: 215–218PubMedCrossRefGoogle Scholar
  18. Jönsson B, Bebbington PE (1994) What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatr 164: 665–673CrossRefGoogle Scholar
  19. Kasper S, Fuger J, Möller HJ (1992) Comparative efficacy of antidepressants. Drugs 43 (Suppl. 2): 11–23PubMedCrossRefGoogle Scholar
  20. Kasper S, Möller HJ (1995) Antidepressive Psychopharmakotherapie. Dt Ärztebl 92: A428–434Google Scholar
  21. Lane R, Baldwin D, Preskorn S (1995) The SSRIs: advantages, disadvantages and differences. J Psychopharmacol 9 (Suppl.): 163–178PubMedGoogle Scholar
  22. McCombs JS, Nichol MB, Stimmel GL, Sclar DA, Beasley CM, Gross LS (1990) The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in the Medicaid population. J Clin Psychiatr 51 (suppl. 6): 60–69Google Scholar
  23. Montgomery SA (1993) Suicide prevention and serotonergic drugs. Int Clin Psychopharmacol 8 (suppl.2): 83–85PubMedCrossRefGoogle Scholar
  24. Montgomery SA, Henry JA, McDonald G, Dinan T, Lader M, Hindmarch I, Clare A, Nutt D (1994) Selective serotonin reuptake inhibitors-meta-analysis of discontinuation rates. Int Clin Psychopharmacol 9: 47–53PubMedCrossRefGoogle Scholar
  25. Nelson JC, Mazure CM, Bowers MB, Jatlow PI (1991) A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 48: 303–307PubMedCrossRefGoogle Scholar
  26. Nolen WA, van de Pute JJ, Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ, Haffmans J (1988) Treatment strategy in depression. Acta Psychiatr Scand 78: 668–675PubMedCrossRefGoogle Scholar
  27. Rickets K, Schweizer E (1990) Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 51 ( Suppl. B): 9–12Google Scholar
  28. Roose SP (1994a) Selective serotonin reuptake inhibitors in refractory depression. In: Nolen WA, Zohar J, Roose SP, Amsterdam JD (eds) Refractory depression: Current strategies and future directions. Wiley & Sons, Chichester, pp 37–46Google Scholar
  29. Roose SP, Glassmann AH, Attia E, Woodring S (1994b) Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 151: 1735–1739PubMedGoogle Scholar
  30. Seth R, Jennings AL, Bindman J, Phillips J, Bergmann K (1992) Combination treatment of noradrenalin and serotonin reuptake inhibitors in resistant depression. Brit J Psychiatr 161: 56z - 565CrossRefGoogle Scholar
  31. Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A, Mason J (1993) Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. Brit Med J 306: 683–687PubMedCrossRefGoogle Scholar
  32. Tyrer P, Marsden CA, Casey P, Seivewright N (1987) Clinical efficacy of paroxetine in resistant depression. J Psychopharmacol 1: 251–257PubMedCrossRefGoogle Scholar
  33. Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K (1989) Ftuoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 50: 447–449PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • C. Baethge
  • M. Bauer

There are no affiliations available

Personalised recommendations